Abstract: The use of botulinum toxin for preparing a drug for preventing hair growth is disclosed. A cosmetic method for preventing hair growth is also disclosed.
Type:
Application
Filed:
March 2, 2005
Publication date:
December 20, 2007
Applicant:
Societe de Conseils de Recherches et D'Applications Scieentifiques
Abstract: A method for implanting or inserting a solid or semisolid formulation containing at least one active principle uses a device comprising one part set inside the body of the patient and which conditions the solid or semisolid form, brings these conditioning action to the deposit site, injects or inserts in this deposit site, and withdraws after injection or insertion, with one part remaining outside and activating the functions of the device. The invention also concerns a sustained-release solid formulation for parenteral administration comprising a homogeneous mixture of an active principle in non-dispersed state and of a biologically compatible and biodegradable excipient, in which the amount of active principle is at least 50% by weight.
Type:
Application
Filed:
August 17, 2007
Publication date:
December 20, 2007
Applicant:
SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION
Abstract: Thiaxozle, oxazole, imidazole, isoxazole and isoxazoline compounds of the formula wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is selected from the various optionally substituted aromatic radicals defined in the specification, B is hydrogen, alkyl or phenyl, R1 and R2 are independently hydrogen, alkyl or cycloalkyl or R1 and R2 taken together with the carbon atom which carries them, form a carbocycle with 3 to 7 members and ? is —NH46R47 or —OR48, R46 and R47 are independently hydrogen, alkyl, cycloalkyl or —(CH2)kCOOR51, R51 is alkyl or haloalkyl and R48 is hydrogen or alkyl having advantageous pharmacological properties which allow their use in therapeutics, for treating neurodegenerative disorders or pain.
Type:
Grant
Filed:
August 10, 2004
Date of Patent:
November 6, 2007
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Inventors:
Pierre-Etienne Chabrier De Lassauniere, Jermiah Harnett, Dennis Bigg, Ann-Marie Liberatore, Jacques Pommier, Jacques Lannoy, Christophe Thurieau, Zheng Xin Dong
Abstract: Heterocyclic dione compounds as disclosed in the specification, compositions thereof and methods for the use thereof, for the treatment of T cell-mediated conditions such as autoimmune diseases and organ graft rejection.
Type:
Application
Filed:
May 22, 2007
Publication date:
November 1, 2007
Applicant:
Societe de Conseils de Recherches et D'Application Scientifiques (S.C.R.A.S.)
Abstract: A compound having a formula selected from the group consisting of wherein the substituents are as defined in the specification. The compounds are useful as intermediates in the preparation of compounds of formula (I), which are useful for inhibiting NO synthase and regenerate antioxidants.
Type:
Grant
Filed:
June 8, 2005
Date of Patent:
October 23, 2007
Assignee:
S.C.R.A.S. Societe de Conseils de Recherches et d'Applications Scientifiques
Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.
Type:
Application
Filed:
December 29, 2006
Publication date:
October 18, 2007
Applicant:
SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S.
Inventors:
Zheng Dong, Resurreccion Miravete, Roland Cherif-Cheikh, Jose-Antonio Rigol, Frederic Lacombe, Maria Maestre
Abstract: The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S.
Type:
Grant
Filed:
December 24, 2002
Date of Patent:
October 9, 2007
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Abstract: The present invention relates to a method of treating insulin resistance or Syndrome X by administering a therapeutically effective amount of a somatostatin agonist or a pharmaceutical composition comprised of a somatostatin agonist to a patient suffering from insulin resistance or Syndrome X.
Type:
Grant
Filed:
February 18, 2003
Date of Patent:
August 14, 2007
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
Inventors:
Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
Abstract: The invention concerns a pharmaceutical composition comprising, as active principle, at least a calpain inhibiting substance and at least a substance trapping reactive oxygen species (ROS), and optionally an acceptable pharmaceutical carrier. The invention also concerns a product comprising at least a calpain inhibiting substance and at least a substance trapping reactive oxygen species (ROS), selectively or not, as combination product, the active principle being separate.
Type:
Grant
Filed:
November 14, 2001
Date of Patent:
July 17, 2007
Assignee:
Societe de Conseils de Recherches et d' 'Applications Scientifiques S.C.R.A.S
Inventors:
Pierre-Etienne Chabrier de Lassauniere, Bernadette Pignol, Serge Auvin
Abstract: The present invention is directed to a novel class of cyclic polypeptides of the formula: (R1)a-AA1-cyclo[AA2-AA3-AA4-AA5-AA6-Cys]-AA7-R2, pharmaceutically acceptable salts thereof, wherein the variables are as defined in the specification, which inhibit the effects of urotensin-II and are useful for treating a variety of diseases and/or conditions characterized by an excess of urotensin-II including ischaemic heart disease, congestive heart failure, portal hypertension, variceal bleeding, hypotension, angina pectoris, myocardial infarction, ulcers, anxiety, schizophrenia, manic depression, delirium, dementia, mental retardation and/or dyskinesias.
Type:
Grant
Filed:
October 19, 2001
Date of Patent:
July 10, 2007
Assignees:
Societe de Conseils de Recherches et d'Applications Scientifiques, SAS, The Administrators of the Tulane Educational Fund
Inventors:
David H. Coy, Wojciech J. Rossowski, John E. Taylor
Abstract: The invention primarily relates to the use of somatostatin or one of the agonistic analogs thereof for producing a medicament serving to regulate the ovarian follicular reserve and, in particular, to reduce the depletion of the ovarian follicular reserve over time in non-menopausal women or to the use of an antagonistic analog of somatostatin for producing a medicament serving to accelerate the start of growing of quiescent follicles in non-menopausal women. The invention also relates to in vitro applications of somatostatin and of agonistic and antagonistic analogs thereof.
Type:
Application
Filed:
October 8, 2004
Publication date:
July 5, 2007
Applicant:
Societe de Conseils de Recherches et D'Application
Abstract: The present invention relates to a method of inhibiting fibrosis in a patient. The method comprises administering a therapeutically effective amount of a somatostatin, a somatostatin agonist or apharmaceutically acceptable salt thereof to said patent.
Type:
Grant
Filed:
September 7, 2004
Date of Patent:
July 3, 2007
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S
Abstract: The present invention is directed to imidazolyl derivatives or pharmaceutically acceptable salts thereof which are useful as agonists or antagonists of somatostatin receptors, having the following formula (I), wherein the substituents are defined in the specification.
Type:
Grant
Filed:
February 4, 2004
Date of Patent:
July 3, 2007
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, SAS
Inventors:
Christophe Alain Thurieau, Lydie Francine Poitout, Marie-Odile Galcera, Christophe Philippe Moinet, Thomas D. Gordon, Barry A. Morgan
Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful thereof comprising said analogues.
Type:
Grant
Filed:
June 6, 2005
Date of Patent:
June 26, 2007
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, SAS
Abstract: The present invention is drawn to compounds of the formula in racemic and enantiomeric form or all combinations of these forms wherein the various substituents are as defined in the application which compounds have a good affinity for certain subtypes of somatostatin receptors and have useful pharmacological properties.
Type:
Grant
Filed:
July 8, 2003
Date of Patent:
May 22, 2007
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (SCRAS)
Abstract: The invention concerns a novel protein modulating cancer cell proliferation. The proteins encoded by the polynucleotides of the invention enable to determine the degree of malignity of abnormal cell proliferation.
Type:
Grant
Filed:
March 1, 2002
Date of Patent:
May 8, 2007
Assignees:
Societe de Conseils de Recherches Et d'Applications Scientifiques (S.C.R.A.S.), Centre National de la Rescherche Scientifique (C.N.R.S.)
Inventors:
Eric Ferrandis, José-Antonio Camara Y Ferrer, Jean Martinez, Christophe Thurieau
Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.
Type:
Application
Filed:
April 21, 2004
Publication date:
April 26, 2007
Applicant:
SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION
Inventors:
Zheng Dong, Yeelena Shen, Jeanne Comstock, Sun Kim
Abstract: Use of botulin toxin to obtain a product intended to be administered intramuscular with lissive effect in treating articular pathologies, particularly coxarthrosis, or arthrosis of the hip, epicondylitis of the elbow and rotator muscle cap pathology of the shoulder.
Type:
Grant
Filed:
January 4, 2002
Date of Patent:
April 24, 2007
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques SAS
Abstract: The present invention pertains to biodegradable polymers comprising a non-polymerizable lactone, biodegradable compositions comprising the polymer and a therapeutic agent, the use of the compositions for the sustained release of therapeutic agents, wherein the therapeutic agent is reversibly immobilized on the polymer matrix using ionic complexation between the latent carboxylic groups present on the lactone bearing polymer matrix and a cationic group on the therapeutic agent.
Type:
Grant
Filed:
April 26, 2005
Date of Patent:
April 17, 2007
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, SAS